Despite recent therapeutic advances, many cancer patients soon develop resistance to currently available treatment options. Thus, new treatment strategies are urgently needed to prevent or overcome therapy resistance. Developing such novel strategies requires a deep understanding of the cancer-driving events and the underlying molecular mechanisms of resistance.

To identify new drug targets and explore novel therapeutic strategies, we use a wide range of state-of-the-art laboratory techniques (including various CRISPR/Cas9 genome engineering technologies) and diverse in vitro and in vivo pre-clinical cancer models. A main focus of our interdisciplinary research is the interplay between oncogenic modulations and the de-regulation of programmed cell death (apoptosis) and how it can be targeted.


Ass.-Prof. Dr.
Michael Dengler  
T: +43 316 385 31428



  • Uncovering new molecular targets for lung cancer therapy on recurrent large genomic amplifications and deletions
  • Establish synthetic lethal relationships in lung cancer using large-scale genetic screening
  • Modelling and overcoming CDK4/6 inhibitor resistance in advanced breast cancer


  • The overarching goal of our research is to identify new cancer drivers and resistance mechanism in various aggressive cancers and help to pave the way to develop novel treatment strategies to overcome/prevent treatment resistance.


Using dual CRISPRko and CRISPRa screens to identify novel targets to overcome cancer drug resistance

  • Duration: 2022-2023
  • Funded by: START Grant, Medical University of Graz

Targeting the apoptotic pathway to overcome therapy resistance in lung cancer

  • Duration: 2022-2023
  • Funded by: MEFOgraz